BIENAIME JEAN JACQUES
SEC CIK 1221590 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| KROS | Keros Therapeutics, Inc. | Dir | 19.6K | $75.8K | — | 8 | 2025-06-04 | 2026-08-17 |
| ASND | Ascendis Pharma A/S | Dir | 2,900 | $699.3K | — | 3 | 2026-05-26 | 2026-08-14 |
| INCY | Incyte | Dir | 24.4K | — | — | 7 | 2022-06-15 | 2026-06-08 |
| IMNM | Immunome Inc. | Dir | 32.9K | $641.2K | $203.8K | 9 | 2024-05-21 | 2026-06-05 |
| BMRN | BIOMARIN PHARMACEUTICAL INC | Dir | 473.8K | — | $43.53M | 70 | 2021-09-09 | 2024-05-20 |
Most active insiders at KROS, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Schneeberger Daniel | 10% | — | $95.66M |
| 2 | Pontifax (China) IV L.P. | 10% | — | $84.98M |
| 3 | Cho Esther | SVP, GC | — | $123.7K |
| 4 | Seehra Jasbir | CEO, Dir | — | $113.4K |
| 5 | Lerner Lorena Raquel | CSO | — | $100.0K |
| 6 | Regnante Keith | CFO | — | $77.5K |
| 7 | BIENAIME JEAN JACQUES | Dir | $75.8K | — |
| 8 | Knowles Julius | Dir | — | $28.2K |
| 9 | Farzan Nima | Dir | — | $28.2K |
| 10 | Seth Alpna | Dir | — | $28.1K |
Transactions 97
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-08-19 16:10 | 2026-08-17 | KROS | Keros Therapeutics, Inc. | BIENAIME JEAN JACQUES | Dir | P - Purchase | $10.27 | +1,000 | 19.6K | +5% | +$10.3K |
| M | 2026-08-18 21:02 | 2026-08-14 | ASND | Ascendis Pharma A/S | BIENAIME JEAN JACQUES | Dir | P - Purchase | $246.33 | +2,000 | 2,900 | +222% | +$492.7K |
| T | 2026-07-17 16:10 | 2026-07-15 | KROS | Keros Therapeutics, Inc. | BIENAIME JEAN JACQUES | Dir | P - Purchase | $10.61 | +1,000 | 18.6K | +6% | +$10.6K |
| T | 2026-06-17 16:55 | 2026-06-15 | KROS | Keros Therapeutics, Inc. | BIENAIME JEAN JACQUES | Dir | P - Purchase | $10.19 | +1,000 | 17.6K | +6% | +$10.2K |
| D | 2026-06-10 16:06 | 2026-06-08 | INCY | Incyte | BIENAIME JEAN JACQUES | Dir | A - Grant | $0.00 | +1,642 | 24.4K | +7% | $0 |
| M | 2026-06-09 17:40 | 2026-06-05 | IMNM | Immunome Inc. | BIENAIME JEAN JACQUES | Dir | S - Sale | $19.41 | -10.5K | 32.9K | -24% | -$203.8K |
| M | 2026-06-09 17:40 | 2026-06-05 | IMNM | Immunome Inc. | BIENAIME JEAN JACQUES | Dir | P - Purchase | $19.45 | +10.5K | 43.4K | +32% | +$204.3K |
| D | 2026-06-05 16:15 | 2026-06-03 | KROS | Keros Therapeutics, Inc. | BIENAIME JEAN JACQUES | Dir | A - Grant | $0.00 | +7,142 | 16.6K | +76% | $0 |
| M | 2026-06-01 16:11 | 2026-05-29 | ASND | Ascendis Pharma A/S | BIENAIME JEAN JACQUES | Dir | P - Purchase | $223.12 | +500 | 900 | +125% | +$111.6K |
| DT | 2026-05-28 16:03 | 2026-05-26 | INCY | Incyte | BIENAIME JEAN JACQUES | Dir | M - OptEx | $84.53 | +15.0K | 35.8K | +72% | +$1.27M |
| DT | 2026-05-28 16:03 | 2026-05-26 | INCY | Incyte | BIENAIME JEAN JACQUES | Dir | F - Tax | $97.10 | -13.1K | 22.8K | -36% | -$1.27M |
| M | 2026-05-27 16:05 | 2026-05-26 | ASND | Ascendis Pharma A/S | BIENAIME JEAN JACQUES | Dir | P - Purchase | $237.80 | +400 | 400 | New | +$95.1K |
| T | 2026-05-19 16:15 | 2026-05-15 | KROS | Keros Therapeutics, Inc. | BIENAIME JEAN JACQUES | Dir | P - Purchase | $10.58 | +1,000 | 9,450 | +12% | +$10.6K |
| 2026-05-19 07:56 | 2026-05-15 | IMNM | Immunome Inc. | BIENAIME JEAN JACQUES | Dir | P - Purchase | $20.70 | +5,000 | 43.4K | +13% | +$103.5K | |
| T | 2026-04-17 16:15 | 2026-04-15 | KROS | Keros Therapeutics, Inc. | BIENAIME JEAN JACQUES | Dir | P - Purchase | $11.70 | +1,000 | 8,450 | +13% | +$11.7K |
| M | 2026-03-12 | 2026-03-10+ | IMNM | Immunome Inc. | BIENAIME JEAN JACQUES | Dir | P - Purchase | $21.84 | +2,000 | 38.4K | +5% | +$43.7K |
| 2026-03-11 | 2026-03-09 | KROS | Keros Therapeutics, Inc. | BIENAIME JEAN JACQUES | Dir | P - Purchase | $11.21 | +2,000 | 7,450 | +37% | +$22.4K | |
| D | 2025-06-12 | 2025-06-10 | INCY | Incyte | BIENAIME JEAN JACQUES | Dir | A - Grant | $0.00 | +2,518 | 20.8K | +14% | $0 |
| D | 2025-06-06 | 2025-06-04 | KROS | Keros Therapeutics, Inc. | BIENAIME JEAN JACQUES | Dir | A - Grant | $0.00 | +5,250 | 5,450 | +2,625% | $0 |
| 2025-06-03 | 2025-06-03 | IMNM | Immunome Inc. | BIENAIME JEAN JACQUES | Dir | P - Purchase | $9.38 | +5,000 | 36.4K | +16% | +$46.9K | |
| 2025-03-26 | 2025-03-25 | IMNM | Immunome Inc. | BIENAIME JEAN JACQUES | Dir | P - Purchase | $7.78 | +7,800 | 31.4K | +33% | +$60.7K | |
| 2025-03-25 | 2025-03-24 | IMNM | Immunome Inc. | BIENAIME JEAN JACQUES | Dir | P - Purchase | $8.21 | +7,000 | 23.6K | +42% | +$57.5K | |
| 2024-08-19 | 2024-08-16 | IMNM | Immunome Inc. | BIENAIME JEAN JACQUES | Dir | P - Purchase | $13.94 | +7,000 | 16.6K | +73% | +$97.6K | |
| D | 2024-06-14 | 2024-06-12 | INCY | Incyte | BIENAIME JEAN JACQUES | Dir | A - Grant | $0.00 | +2,830 | 18.3K | +18% | $0 |
| 2024-05-22 | 2024-05-21 | IMNM | Immunome Inc. | BIENAIME JEAN JACQUES | Dir | P - Purchase | $13.57 | +2,000 | 9,615 | +26% | +$27.1K | |
| 2024-05-21 | 2024-05-20 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | Dir | F - Tax | $77.05 | -1,202 | 473.8K | -0.3% | -$92.6K | |
| DM | 2024-05-13 | 2024-05-09+ | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | Dir | S - Sale+OE | $81.38 | -40.0K | 475.0K | -8% | -$3.26M |
| DM | 2024-05-13 | 2024-05-09+ | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | Dir | M - OptEx | $63.10 | +40.0K | 495.0K | +9% | +$2.52M |
| DM | 2024-04-15 | 2024-04-11+ | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | Dir | S - Sale+OE | $91.12 | -40.0K | 475.0K | -8% | -$3.65M |
| DM | 2024-04-15 | 2024-04-11+ | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | Dir | M - OptEx | $63.10 | +40.0K | 495.0K | +9% | +$2.52M |
| 2024-03-19 | 2024-03-15 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | Dir | F - Tax | $83.87 | -85.2K | 475.0K | -15% | -$7.15M | |
| M | 2024-03-07 | 2024-03-05+ | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | Dir | S - Sale | $86.11 | -2,000 | 560.2K | -0.4% | -$172.2K |
| M | 2024-02-29 | 2024-02-27 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | Dir | A - Grant | $0.00 | +143.6K | 563.2K | +34% | $0 |
| 2024-02-29 | 2024-02-27 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | Dir | S - Sale | $90.35 | -1,000 | 562.2K | -0.2% | -$90.3K | |
| D | 2024-02-12 | 2024-01-18 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | Dir | L - Small Acq | $92.60 | +40 | 419.6K | +0.0% | +$3,704 |
| DM | 2024-02-12 | 2024-02-08+ | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | Dir | M - OptEx | $63.10 | +30.0K | 434.6K | +7% | +$1.89M |
| DM | 2024-02-12 | 2024-02-08+ | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | Dir | S - Sale+OE | $89.03 | -30.0K | 419.6K | -7% | -$2.67M |
| DM | 2024-01-11 | 2024-01-09+ | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | Dir | M - OptEx | $63.10 | +20.0K | 435.2K | +5% | +$1.26M |
| D | 2024-01-11 | 2024-01-08 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | Dir | L - Small Acq | $99.05 | +50 | 425.2K | +0.0% | +$4,952 |
| DM | 2024-01-11 | 2024-01-09+ | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | Dir | S - Sale+OE | $97.28 | -20.0K | 425.2K | -4% | -$1.95M |
| D | 2023-12-22 | 2023-12-21 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | Dir | M - OptEx | $63.10 | +10.0K | 435.1K | +2% | +$631.0K |
| D | 2023-12-22 | 2023-12-21 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | Dir | S - Sale+OE | $93.99 | -10.0K | 425.1K | -2% | -$939.9K |
| 2023-12-12 | 2023-10-04 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | Dir | L - Small Acq | $85.57 | +10 | 422.7K | +0.0% | +$855.70 | |
| 2023-12-12 | 2023-12-01 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | Dir | A - Grant | $0.00 | +2,370 | 425.1K | +0.6% | $0 | |
| M | 2023-08-09 | 2023-08-07+ | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | S - Sale | $88.21 | -10.0K | 422.7K | -2% | -$882.1K |
| D | 2023-06-16 | 2023-06-14 | INCY | Incyte | BIENAIME JEAN JACQUES | Dir | A - Grant | $0.00 | +2,505 | 15.5K | +19% | $0 |
| DM | 2023-05-16 | 2023-05-12 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | M - OptEx | $67.81 | +46.5K | 465.3K | +11% | +$3.15M |
| DM | 2023-05-16 | 2023-05-12 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | F - Tax | $93.93 | -40.0K | 466.4K | -8% | -$3.76M |
| DM | 2023-05-15 | 2023-05-11 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | S - Sale+OE | $94.67 | -30.0K | 431.8K | -6% | -$2.84M |
| D | 2023-05-15 | 2023-05-11 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | M - OptEx | $67.81 | +30.0K | 456.2K | +7% | +$2.03M |
| DM | 2023-05-11 | 2023-05-09+ | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | M - OptEx | $67.81 | +60.0K | 456.2K | +15% | +$4.07M |
| DM | 2023-05-11 | 2023-05-09+ | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | S - Sale+OE | $94.89 | -60.0K | 426.2K | -12% | -$5.69M |
| D | 2023-05-11 | 2023-04-28 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | A - Grant | $66.88 | +317 | 426.2K | +0.1% | +$21.2K |
| D | 2023-04-12 | 2023-04-10 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | S - Sale+OE | $99.56 | -10.0K | 425.9K | -2% | -$995.6K |
| D | 2023-04-12 | 2023-04-10 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | M - OptEx | $67.81 | +10.0K | 435.9K | +2% | +$678.1K |
| D | 2023-04-10 | 2023-04-06 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | S - Sale+OE | $96.13 | -10.0K | 425.9K | -2% | -$961.3K |
| D | 2023-04-10 | 2023-04-06 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | M - OptEx | $67.81 | +10.0K | 435.9K | +2% | +$678.1K |
| D | 2023-03-17 | 2023-03-15 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | A - Grant | $0.00 | +36.1K | 524.0K | +7% | $0 |
| DM | 2023-03-17 | 2023-03-15+ | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | F - Tax | $92.86 | -98.1K | 514.5K | -16% | -$9.11M |
| DM | 2023-03-14 | 2023-03-10+ | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | M - OptEx | $67.81 | +23.0K | 502.9K | +5% | +$1.56M |
| DM | 2023-03-14 | 2023-03-10+ | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | S - Sale+OE | $91.64 | -23.0K | 487.9K | -5% | -$2.11M |
| M | 2023-03-02 | 2023-02-28 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | A - Grant | $0.00 | +167.5K | 487.9K | +52% | $0 |
| DM | 2023-02-14 | 2023-02-10+ | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | M - OptEx | $67.81 | +21.0K | 335.3K | +7% | +$1.42M |
| DM | 2023-02-14 | 2023-02-10+ | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | S - Sale+OE | $109.84 | -21.0K | 320.3K | -6% | -$2.31M |
| DMI | 2023-02-14 | 2023-02-07 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | G - Gift | $0.00 | 0 | 247.3K | New | $0 |
| DM | 2023-01-18 | 2023-01-13+ | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | M - OptEx | $67.81 | +20.0K | 330.4K | +6% | +$1.36M |
| DM | 2023-01-18 | 2023-01-13+ | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | S - Sale+OE | $111.90 | -20.0K | 320.4K | -6% | -$2.24M |
| 2022-12-15 | 2022-12-13 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | S - Sale | $106.89 | -1,000 | 320.4K | -0.3% | -$106.9K | |
| M | 2022-12-06 | 2022-12-02 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | S - Sale | $103.98 | -1,500 | 321.4K | -0.5% | -$156.0K |
| 2022-12-06 | 2022-11-02 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | L - Small Acq | $86.12 | +100 | 322.9K | +0.0% | +$8,612 | |
| 2022-11-01 | 2022-10-31 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | S - Sale | $86.55 | -1,500 | 322.8K | -0.5% | -$129.8K | |
| 2022-10-18 | 2022-10-14 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | S - Sale | $89.89 | -4,000 | 324.3K | -1% | -$359.6K | |
| M | 2022-08-16 | 2022-08-12+ | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | S - Sale | $94.95 | -7,000 | 328.3K | -2% | -$664.6K |
| D | 2022-06-17 | 2022-06-15 | INCY | Incyte | BIENAIME JEAN JACQUES | Dir | A - Grant | $0.00 | +2,144 | 13.0K | +20% | $0 |
| DM | 2022-05-09 | 2022-05-05+ | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | M - OptEx | $37.46 | +30.0K | 345.3K | +10% | +$1.12M |
| DM | 2022-05-09 | 2022-05-05+ | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | S - Sale+OE | $82.05 | -30.0K | 335.3K | -8% | -$2.46M |
| D | 2022-05-09 | 2022-04-29 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | A - Grant | $62.41 | +341 | 335.3K | +0.1% | +$21.3K |
| DM | 2022-05-02 | 2022-04-28+ | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | M - OptEx | $37.46 | +25.0K | 355.0K | +8% | +$936.5K |
| DM | 2022-05-02 | 2022-04-28+ | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | S - Sale+OE | $83.42 | -25.0K | 335.0K | -7% | -$2.09M |
| D | 2022-04-20 | 2022-04-18 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | S - Sale+OE | $81.91 | -20.0K | 335.0K | -6% | -$1.64M |
| D | 2022-04-20 | 2022-04-18 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | M - OptEx | $37.46 | +20.0K | 355.0K | +6% | +$749.2K |
| D | 2022-04-18 | 2022-04-14 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | M - OptEx | $37.46 | +10.0K | 345.0K | +3% | +$374.6K |
| D | 2022-04-18 | 2022-04-14 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | S - Sale+OE | $83.66 | -10.0K | 335.0K | -3% | -$836.6K |
| D | 2022-03-17 | 2022-03-15 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | A - Grant | $0.00 | +40.3K | 378.8K | +12% | $0 |
| DM | 2022-03-17 | 2022-03-15+ | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | F - Tax | $78.58 | -43.9K | 340.5K | -11% | -$3.45M |
| DM | 2022-03-14 | 2022-03-10+ | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | M - OptEx | $37.46 | +30.0K | 353.6K | +9% | +$1.12M |
| DM | 2022-03-14 | 2022-03-10+ | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | S - Sale+OE | $77.69 | -30.0K | 338.6K | -8% | -$2.33M |
| 2022-03-10 | 2022-03-08 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | A - Grant | $0.00 | +34.8K | 338.6K | +11% | $0 | |
| DM | 2022-01-14 | 2022-01-12+ | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | S - Sale+OE | $88.43 | -10.0K | 303.8K | -3% | -$884.3K |
| D | 2022-01-14 | 2021-12-21 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | L - Small Acq | $89.22 | +100 | 303.8K | +0.0% | +$8,922 |
| DM | 2022-01-14 | 2022-01-12+ | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | M - OptEx | $37.46 | +10.0K | 308.8K | +3% | +$374.6K |
| DM | 2021-12-17 | 2021-12-15+ | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | S - Sale+OE | $83.69 | -12.0K | 303.7K | -4% | -$1.00M |
| DM | 2021-12-17 | 2021-12-15+ | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | M - OptEx | $37.46 | +12.0K | 309.7K | +4% | +$449.5K |
| D | 2021-12-17 | 2021-12-10 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | G - Gift | $0.00 | -700 | 303.7K | -0.2% | $0 |
| 2021-12-02 | 2021-12-01 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | S - Sale | $87.22 | -1,500 | 304.4K | -0.5% | -$130.8K | |
| 2021-12-02 | 2021-09-09 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | L - Small Acq | $78.77 | +50 | 305.9K | +0.0% | +$3,938 | |
| D | 2021-10-22 | 2021-10-20 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | CEO, Dir | M - OptEx | $37.46 | +1,000 | 305.8K | +0.3% | +$37.5K |
Purchase Sale Sale after option exercise All abbreviations